BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9024707)

  • 1. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma.
    Nakata B; Chung YS; Nishimura S; Nishihara T; Sakurai Y; Sawada T; Okamura T; Kawabe J; Ochi H; Sowa M
    Cancer; 1997 Feb; 79(4):695-9. PubMed ID: 9024707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between 18F-fluorodeoxyglucose positron emission tomography and pathologic differentiation in pancreatic cancer.
    Ahn SJ; Park MS; Lee JD; Kang WJ
    Ann Nucl Med; 2014 Jun; 28(5):430-5. PubMed ID: 24623151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer.
    Nakata B; Nishimura S; Ishikawa T; Ohira M; Nishino H; Kawabe J; Ochi H; Hirakawa K
    Int J Oncol; 2001 Jul; 19(1):53-8. PubMed ID: 11408922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma.
    Zimny M; Fass J; Bares R; Cremerius U; Sabri O; Buechin P; Schumpelick V; Buell U
    Scand J Gastroenterol; 2000 Aug; 35(8):883-8. PubMed ID: 10994629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
    Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
    Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET.
    Higashi T; Sakahara H; Torizuka T; Nakamoto Y; Kanamori S; Hiraoka M; Imamura M; Nishimura Y; Tamaki N; Konishi J
    J Nucl Med; 1999 Sep; 40(9):1424-33. PubMed ID: 10492360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma.
    Benyounes H; Smith FW; Campbell C; Evans NT; Norton MY; Mikecz P; Heys SD; Bruce D; Eremin O; Sharp PF
    Nucl Med Commun; 1995 Jul; 16(7):575-80. PubMed ID: 7478396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases.
    Zimny M; Bares R; Fass J; Adam G; Cremerius U; Dohmen B; Klever P; Sabri O; Schumpelick V; Buell U
    Eur J Nucl Med; 1997 Jun; 24(6):678-82. PubMed ID: 9169578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors.
    Higashi T; Tamaki N; Torizuka T; Nakamoto Y; Sakahara H; Kimura T; Honda T; Inokuma T; Katsushima S; Ohshio G; Imamura M; Konishi J
    J Nucl Med; 1998 Oct; 39(10):1727-35. PubMed ID: 9776278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.
    Inokuma T; Tamaki N; Torizuka T; Magata Y; Fujii M; Yonekura Y; Kajiyama T; Ohshio G; Imamura M; Konishi J
    Radiology; 1995 May; 195(2):345-52. PubMed ID: 7724751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma.
    Sperti C; Pasquali C; Chierichetti F; Ferronato A; Decet G; Pedrazzoli S
    J Gastrointest Surg; 2003 Dec; 7(8):953-9; discussion 959-60. PubMed ID: 14675704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between apparent diffusion coefficients on diffusion-weighted MRI and standardized uptake value on FDG-PET/CT in pancreatic adenocarcinoma.
    Sakane M; Tatsumi M; Kim T; Hori M; Onishi H; Nakamoto A; Eguchi H; Nagano H; Wakasa K; Hatazawa J; Tomiyama N
    Acta Radiol; 2015 Sep; 56(9):1034-41. PubMed ID: 25267921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results.
    Bares R; Klever P; Hellwig D; Hauptmann S; Fass J; Hambuechen U; Zopp L; Mueller B; Buell U; Schumpelick V
    Nucl Med Commun; 1993 Jul; 14(7):596-601. PubMed ID: 8355920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
    Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
    J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study.
    Higashi T; Tamaki N; Honda T; Torizuka T; Kimura T; Inokuma T; Ohshio G; Hosotani R; Imamura M; Konishi J
    J Nucl Med; 1997 Sep; 38(9):1337-44. PubMed ID: 9293783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma.
    Reske SN; Grillenberger KG; Glatting G; Port M; Hildebrandt M; Gansauge F; Beger HG
    J Nucl Med; 1997 Sep; 38(9):1344-8. PubMed ID: 9293784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.
    Chang JC; Kundranda M
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?
    Buck AC; Schirrmeister HH; Guhlmann CA; Diederichs CG; Shen C; Buchmann I; Kotzerke J; Birk D; Mattfeldt T; Reske SN
    J Nucl Med; 2001 May; 42(5):721-5. PubMed ID: 11337566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.